276 related articles for article (PubMed ID: 33365280)
1. Complement Inhibition for the Treatment of Myasthenia Gravis.
Mantegazza R; Vanoli F; Frangiamore R; Cavalcante P
Immunotargets Ther; 2020; 9():317-331. PubMed ID: 33365280
[TBL] [Abstract][Full Text] [Related]
2. Myasthenia gravis: the role of complement at the neuromuscular junction.
Howard JF
Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
Jiao L; Li H; Guo S
J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
[TBL] [Abstract][Full Text] [Related]
4. Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review.
Waheed W; Newman E; Aboukhatwa M; Moin M; Tandan R
Ther Clin Risk Manag; 2022; 18():699-719. PubMed ID: 35855752
[TBL] [Abstract][Full Text] [Related]
5. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
Howard JF; Vissing J; Gilhus NE; Leite MI; Utsugisawa K; Duda PW; Farzaneh-Far R; Murai H; Wiendl H
Expert Opin Investig Drugs; 2021 May; 30(5):483-493. PubMed ID: 33792453
[TBL] [Abstract][Full Text] [Related]
6. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
7. Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities.
Rose N; Holdermann S; Callegari I; Kim H; Fruh I; Kappos L; Kuhle J; Müller M; Sanderson NSR; Derfuss T
Acta Neuropathol; 2022 Nov; 144(5):1005-1025. PubMed ID: 36074148
[TBL] [Abstract][Full Text] [Related]
8. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
9. Ravulizumab: A Review in Generalised Myasthenia Gravis.
Kang C
Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
[TBL] [Abstract][Full Text] [Related]
10. Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.
Vanoli F; Mantegazza R
Neurotherapeutics; 2022 Apr; 19(3):897-910. PubMed ID: 35165857
[TBL] [Abstract][Full Text] [Related]
11. Role of complement in myasthenia gravis.
San PP; Jacob S
Front Neurol; 2023; 14():1277596. PubMed ID: 37869140
[TBL] [Abstract][Full Text] [Related]
12. Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies.
Ozawa Y; Uzawa A; Onishi Y; Yasuda M; Kojima Y; Kuwabara S
Muscle Nerve; 2023 Nov; 68(5):798-804. PubMed ID: 37705312
[TBL] [Abstract][Full Text] [Related]
13. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
Uzawa A; Kuwabara S
Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
[TBL] [Abstract][Full Text] [Related]
14. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence.
Vu T; Wiendl H; Katsuno M; Reddel SW; Howard JF
Neuropsychiatr Dis Treat; 2023; 19():2639-2655. PubMed ID: 38059203
[TBL] [Abstract][Full Text] [Related]
15. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
Datta S; Singh S; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
[TBL] [Abstract][Full Text] [Related]
16. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients.
Lekova E; Zelek WM; Gower D; Spitzfaden C; Osuch IH; John-Morris E; Stach L; Gormley D; Sanderson A; Bridges A; Wear ER; Petit-Frere S; Burden MN; Priest R; Wattam T; Kitchen SJ; Feeney M; Davis S; Morgan BP; Nichols EM
Front Immunol; 2022; 13():968206. PubMed ID: 36148231
[TBL] [Abstract][Full Text] [Related]
17. Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.
Stascheit F; Chuquisana O; Keller CW; Ambrose PA; Hoffmann S; Gross CC; Lehnerer S; Wiendl H; Willcox N; Meisel A; Lünemann JD
Eur J Neurol; 2023 May; 30(5):1409-1416. PubMed ID: 36752022
[TBL] [Abstract][Full Text] [Related]
18. Complement Inhibitor Therapy for Myasthenia Gravis.
Albazli K; Kaminski HJ; Howard JF
Front Immunol; 2020; 11():917. PubMed ID: 32582144
[TBL] [Abstract][Full Text] [Related]
19. A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies.
Plomp JJ; Huijbers MGM; Verschuuren JJGM; Borodovsky A
J Neurosci Methods; 2022 May; 373():109551. PubMed ID: 35247492
[TBL] [Abstract][Full Text] [Related]
20. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
Xiao H; Wu K; Liang X; Li R; Lai KP
Front Immunol; 2021; 12():715036. PubMed ID: 34456922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
